SCHEMBL8335601

SCHEMBL8335601

NC(=O)c1cnn2c1NCC=C2c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK2 O43353 1/20 0.46
MAP2K1 Q02750 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
DYRK1B Q9Y463 1/20 0.43
RAB9A P51151 2/20 0.38
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
BCAT2 O15382 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36
HSD17B10 Q99714 1/20 0.36
JAK1 P23458 4/20 0.36
JAK3 P52333 4/20 0.36
CDC7 O00311 2/20 0.36
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
CCNA1 P78396 1/20 0.36
JAK2 O60674 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9869104 0.89 MKNK1 (0.43) JAK1JAK3MAPK14
SCHEMBL8339312 0.86 CDC7 (0.43) RIPK2LMNAKDM4EALDH1A1MAPK1
SCHEMBL8337977 0.86 TLR8 (0.50) RIPK2RAB9ASMN1; SMN2ALDH1A1JAK1
SCHEMBL8337425 0.83 KDM4E (0.52) RAB9ASMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL10555321 0.80 KEAP1 (0.42) LMNAKDM4EALDH1A1MAPK14KEAP1
SCHEMBL30147332 0.65 RIPK2 (0.69) RIPK2RAB9ALMNASMN1; SMN2KDM4E
SCHEMBL9728839 0.64 PLAT (0.36) RIPK2MAP2K1CLK4DYRK1BKDM4E
SCHEMBL2743084 0.63 RIPK2 (1.00) RIPK2RAB9ALMNASMN1; SMN2ALDH1A1
SCHEMBL10554470 0.63
SCHEMBL10560055 0.63 MKNK1 (0.41) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0957918-A1 METHOD OF TREATING OR INHIBITING NEUTROPENIA American Cyanamid Company (US) 1999-11-24 EP disclosed
US-5932585-A Method of treating or inhibiting neutropenia AMERICAN CYANAMID COMPANY (US) 1999-08-03 US disclosed
WO-1998026781-A1 METHOD OF TREATING OR INHIBITING NEUTROPENIA AMERICAN CYANAMID COMPANY (US) 1998-06-25 WO disclosed
US-5013737-A Hypotensive, anxiolytic, cognitive disorders AMERICAN CYANAMID COMPANY (US) 1991-05-07 US disclosed
US-4916137-A 5-(Substituted-amino)-8-(phenyl or substituted-phenyl)-3H,6H-1,4,5A,8A-tetraazaacenaphthylen-3-ones and treatment of neural behavior disorders AMERICAN CYANAMID COMPANY (US) 1990-04-10 US disclosed
EP-0329940-A1 5-(substituted)amino)-8- (phenyl or substituted phenyl)-3H,6H-1,2,5,a,8 a-tetraazaacenaphthylen-3-ones AMERICAN CYANAMID COMPANY (US) 1989-08-30 EP disclosed